Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development
Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....
Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives
The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...
Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...
China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology
The National Development and Reform Commission (NDRC) of China has announced the release of the...
China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans
The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...
Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds
The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...
China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion
China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...
Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development
On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...
Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern
The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...
China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...
Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...